"Screening for liver fibrosis was associated with improved self-reported alcohol consumption, diet, exercise and weight after 6 months among patients at risk for liver disease, with lifestyle changes persisting through 2 years." https://t.co/O7733N2rlU
#FibrosisTreatment
Explore the latest findings from the FASCINATE-2 trial on Denifanstat for NASH with fibrosis. This research brings us closer to effective treatments for NASH and fibrosis: https://t.co/INMEfYY8Nj
#NASHResearch#FibrosisTreatment
Sonic Incytes is gearing up for @NashTagConf 2024! 📷
We'll be in Park City, UT from January 4-6, 2024. Come watch a live demo, or have your own liver scanned and discover how Velacur™ can elevate your practice.
#LiverHealth#FattyLiverDisease#NASH#NAFLD#LiverDisease
Meet the PathAI team at the @NashTagConf Conference this week in Park City, UT!
Our AIM-NASH product offers unparalleled, reliable detection & quantification of histologic features of NASH. Watch below & stop by our table at NASH-TAG to learn more! https://t.co/0nEHXrjbDy
Inventiva's leadership team will attend the @NashTagConf in Park City, Jan 4-6. We are excited to connect with clinicians, researchers, and experts, gaining insights into #NASH/#MASH and #liverfibrosis. Learn more: https://t.co/IescVShTzI
This Saturday, we’ll be presenting data on the anti-inflammatory and anti-fibrotic properties of #pemvidutide in subjects with #MASLD at the @NashTagConf in Park City, Utah. Learn more: https://t.co/fJTxDsysn4 #NASHTAG2024
Fabulous summary slide @mcharltonmd comparing efficacy of current wt loss therapies including surgical options which create the largest weight loss
So many exciting options but still many unanswered Q which we will discuss over next 2d
#2024NASHTAG@NashTagConf
We’re proud to have our CEO Lorraine Stiehl participating in Friday’s Fireside Chat at @NashTagConf! The conference brings together leading clinicians, researchers, & organizations to focus on NASH advances and challenges. #NASHTAG#AdvancingNASH#LiverHealth#CuttingEdgeResearch
Steve Harrison summarizing AI is here to stay to help fill unmet needs in #MASH and helps combat the placebo effect that has plagued our trials for years
#2024NASHTAG@NashTagConf
📊 A recent survey reveals that individuals who received a NASH diagnosis grasp the severity but face challenges in fully understanding the disease. This article sheds light on patient perspectives: https://t.co/XYwnRw8GpO
#NASH#PatientExperience#LiverHealth